Why the study?
What is the optimal antithrombotic therapy to reduce ischaemic events and prevent graft occlusion in patients after coronary artery bypass graft surgery?
What is the optimal antithrombotic therapy to reduce ischaemic events and prevent graft occlusion in patients after coronary artery bypass graft surgery?
This consensus statement provides tailored recommendations for antithrombotic therapy after CABG based on individual ischaemic and bleeding risks.
Antithrombotic therapy is essential after coronary artery bypass graft surgery to reduce ischaemic events and prevent graft occlusion. Although aspirin remains the most commonly used agent, in higher-risk patients, dual antiplatelet therapy or combining antiplatelet therapy with oral anticoagulation may be beneficial, but this increases bleeding risk. The choice of antithrombotic therapy should be tailored to each patient, based on their ischaemic and bleeding risks, and regularly reassessed. Here, the scientific evidence underlying the key aspects of the choice of antithrombotic therapy after coronary artery bypass grafting is reviewed. Consensus statements for best clinical practice are provided and areas requiring further research are highlighted.
No takes yet. Share an insight, caveat, or question.
Sandner et al. (2025) conducted a review in Post-coronary artery bypass graft surgery. Antithrombotic therapy was evaluated. Antithrombotic therapy after coronary artery bypass grafting should be tailored to individual ischaemic and bleeding risks, with aspirin as the standard and dual therapy considered for higher-risk patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: